Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
GlaxoSmithKline
Start Date
March 12, 2020
End Date
April 4, 2024
Administered By
Duke Cancer Institute
Awarded By
GlaxoSmithKline
Start Date
March 12, 2020
End Date
April 4, 2024